Jeff Aronin has combined the principles of entrepreneurship and philanthropy to create a business that is concerned with human needs. He today serves as the CEO of Paragon Biosciences, a company that is dedicated to assisting ailing patients who were once thought to be beyond the help of conventional medicine.
Born in 1967, Jeff Aronin would obtain a Bachelor of Science degree from Northern Illinois University and an MBA from DePaul University. Despite his background in business, he developed an interest in medical research while observing the treatment of a child suffering from epilepsy. This experience served to motivate his desire to find drugs as an alternative to surgery in the treatment of serious disorders. His experiences lead to Jeff Aronin’s creation in 2000 of the firm Ovation Pharmaceuticals. Ovation was purchased in 2009 by the Danish firm Lundbeck, which produces and markets drugs used in the treatment of many disorders, including epilepsy and schizophrenia.
The year after the purchase of Ovation, Jeff Aronin became the chief executive of Paragon, further advancing his long-term quest to find new drugs in the treatment of diseases. Going beyond conventional medical practices, Paragon developed a network of companies that employ researchers with specialized knowledge in certain areas. This more than a dozen different drugs that have received approval by the U.S. Food and Drug Administration.
Under the leadership of Jeff Aronin, Paragon follows the principle that each patient receives assistance that is highly personalized. The company uses the most advanced techniques in its development of new medications and new treatment methods. Jeff Aronin’s role in these advances comes from his continued financial support of the research teams working on these new products.
Outside of his work at Paragon, Jeff Aronin’s philanthropic activities include support for such research organizations as the Huntington’s Disease Society of America and the Pediatric Epilepsy Research Foundation. In 2017, he was honored by the Weizmann Institute of Science.